NCT02662621 2025-06-05
EXODIAG
Centre Georges Francois Leclerc
Phase NA Completed
Clinical Trials
17 trialsNCT04804137 2024-01-17
RICEPS
University Hospital, Tours
Completed
NCT00611598 2023-03-29
DNA Repair and Genetic Susceptibility to Lung Cancer
Memorial Sloan Kettering Cancer Center
Completed
NCT00568282 2022-06-22
LUN0017
Stanford University
Completed
NCT01785342 2022-03-15
DECAMP-1
Boston University
Completed
NCT03047616 2021-04-19
A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer
Abramson Cancer Center at Penn Medicine
Completed
NCT02853006 2020-03-19
ECTOPIC/MUTAS
University Hospital, Grenoble
Phase NA Completed
NCT03549546 2019-07-26
POIR
Centre Hospitalier Universitaire de Saint Etienne
Phase NA Completed
NCT02281214 2019-01-04
ALCAPONE
Centre Georges Francois Leclerc
Phase NA Completed
NCT01710319 2018-05-07
MechLungCa
Washington University School of Medicine
Completed
NCT00897650 2017-07-19
Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
Vanderbilt-Ingram Cancer Center
Completed
NCT02309567 2016-11-01
Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?
Cumhuriyet University
Completed
NCT01209520 2015-02-24
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
University of Miami
Phase NA Completed
NCT01578018 2012-08-10
Tumor Markers in Lung Cancer: DCAMLK-1LK-1
University of Oklahoma
Phase NA Completed
NCT00422500 2012-08-02
Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer
M.D. Anderson Cancer Center
Completed
NCT00745160 2011-03-30
Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes
Memorial Sloan Kettering Cancer Center
Completed
NCT00579462 2010-12-01
Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer
Memorial Sloan Kettering Cancer Center
Completed